These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22686936)

  • 1. Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer.
    Yang Y; Hu Y; Wang Y; Li J; Liu F; Huang L
    Mol Pharm; 2012 Aug; 9(8):2280-9. PubMed ID: 22686936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
    Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
    Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC.
    Zhang Y; Schwerbrock NM; Rogers AB; Kim WY; Huang L
    Mol Ther; 2013 Aug; 21(8):1559-69. PubMed ID: 23774791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis.
    Yang Y; Li J; Liu F; Huang L
    Mol Ther; 2012 Mar; 20(3):609-15. PubMed ID: 22186791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles.
    Yu H; Zou Y; Jiang L; Yin Q; He X; Chen L; Zhang Z; Gu W; Li Y
    Biomaterials; 2013 Apr; 34(11):2738-47. PubMed ID: 23352573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo.
    Das J; Das S; Paul A; Samadder A; Bhattacharyya SS; Khuda-Bukhsh AR
    Toxicol Lett; 2014 Mar; 225(3):454-66. PubMed ID: 24440344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral delivery and therapeutic efficacy of nanoparticle-encapsulated anti-tumor siRNA following intrapulmonary administration for potential treatment of lung cancer.
    Kanehira Y; Togami K; Ishizawa K; Sato S; Tada H; Chono S
    Pharm Dev Technol; 2019 Nov; 24(9):1095-1103. PubMed ID: 31204552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle delivery of HIF1α siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer.
    Chen WH; Lecaros RL; Tseng YC; Huang L; Hsu YC
    Cancer Lett; 2015 Apr; 359(1):65-74. PubMed ID: 25596376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 knockdown mediated by a triazine-modified dendrimer in the treatment of non-small cell lung cancer.
    Huang Q; Li L; Li L; Chen H; Dang Y; Zhang J; Shao N; Chang H; Zhou Z; Liu C; He B; Wei H; Xiao J
    Oncotarget; 2016 Jul; 7(28):44013-44022. PubMed ID: 27259273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer.
    Zhang W; Xu W; Lan Y; He X; Liu K; Liang Y
    Int J Nanomedicine; 2019; 14():5287-5301. PubMed ID: 31406460
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted nanoparticles deliver siRNA to melanoma.
    Chen Y; Bathula SR; Yang Q; Huang L
    J Invest Dermatol; 2010 Dec; 130(12):2790-8. PubMed ID: 20686495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy.
    Zhang Y; Peng L; Mumper RJ; Huang L
    Biomaterials; 2013 Nov; 34(33):8459-68. PubMed ID: 23932296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y; Li S; Li J; Wang D; Li Q
    Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
    McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
    Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Functional LipoMET Mediates Envelope-type Nanoparticles to Combinational Oncogene Silencing and Tumor Growth Inhibition.
    Shi K; Zhao Y; Miao L; Satterlee A; Haynes M; Luo C; Musetti S; Huang L
    Mol Ther; 2017 Jul; 25(7):1567-1579. PubMed ID: 28274796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts.
    Chen S; Liu X; Gong W; Yang H; Luo D; Zuo X; Li W; Wu P; Liu L; Xu Q; Ji A
    Oncol Rep; 2013 Jan; 29(1):260-8. PubMed ID: 23117577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
    Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
    Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy.
    Chen Y; Wu JJ; Huang L
    Mol Ther; 2010 Apr; 18(4):828-34. PubMed ID: 20068551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
    Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
    Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.